With so much attention paid to adenosine diphosphate receptor blockers, is there still a role for aspirin resistance?
Servicio de Cardiología, Hospital General Universitario de Santa Lucía, Cartagena, Murcia, Spain. Electronic address: lconsue@gmail.com.
Luciano
L
Consuegra-Sánchez
Servicio de Cardiología, Hospital General Universitario de Santa Lucía, Cartagena, Murcia, Spain.
Derek
D
Dau
Servicio de Cardiología, Hospital General Universitario de Santa Lucía, Cartagena, Murcia, Spain.
Leticia
L
Jaulent
Sección de Cardiología, Departamento de Medicina Interna, Hospital Don Benito-Villanueva, Don Benito, Badajoz, Spain.
Daniel
D
Fernández-Bergés
Servicio de Cardiología, Hospital General Universitario de Santa Lucía, Cartagena, Murcia, Spain.
Francisco
F
Picó
Servicio de Cardiología, Hospital General Universitario de Santa Lucía, Cartagena, Murcia, Spain.
Manuel
M
Villegas
D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D004351:Drug Resistance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010979:Platelet Function Tests; D011379:Prognosis; D058919:Purinergic P2 Receptor Antagonists / Q000627:therapeutic use*; D018048:Receptors, Purinergic P2 / Q000187:drug effects*
D010975:Platelet Aggregation Inhibitors; D058919:Purinergic P2 Receptor Antagonists; D018048:Receptors, Purinergic P2; D001241:Aspirin